product name Mesalamine
Description: Mesalamine, also known as Asacol and 5-ASA, is a specific inhibitor of TNFα-induced IKK activity, it is used to treat inflammatory bowel disease. Mesalamine is structurally related to the salicylates, which is active in inflammatory bowel disease. Mesalamine is used in the treatment of ulcerative colitis.
References: J Biol Chem. 1999 Sep 10;274(37):26448-53.
153.14
Formula
C7H7NO3
CAS No.
89-57-6
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 31 mg/mL (202.4 mM)
Water: <1 mg/mL
Ethanol: 31 mg/mL (202.4 mM)
Solubility (In vivo)
Synonyms
5-Aminosalicylic acid
other peoduct :
| In Vitro |
In vitro activity: Mesalamine inhibits the enzyme 3-hydroxysteroid dehydrogenase, involved in the reversible conversion between DHP and THP, and therefore may affect the local actions of DHP and THP in the brain. Mesalamine, an anti-inflammatory aminosalicylate, dose-dependently inhibits IL-1-stimulated NF-kappaB-dependent transcription without preventing IkappaB degradation or nuclear translocation and DNA binding of the transcriptionally active NF-kappaB proteins, RelA, c-Rel, or RelB. Mesalamine is found to inhibit IL-1-stimulated RelA phosphorylation. Mesalamine increases cell adhesion which is measured by cell adhesion assay and transcellular-resistance measurement. Mesalamine treatment restores membranous expression of adhesion molecules E-cadherin and β-catenin. Mesalamine or sulfasalazine (2 mM), but not sulfapyridine, significantly reduces the expression of the TC22 transcript and significantly reduces the expression of TC22 protein in a dose-dependent and reversible manner. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | J Biol Chem. 1999 Sep 10;274(37):26448-53. |
